Comparative effectiveness research in oncology methodology: Observational data

Journal of Clinical Oncology

Volumn 30, Issue 34, 2012, Pages 4215-4222

  Hershman, Dawn L ^a   Wright, Jason D ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER RESEARCH; CLINICAL DECISION MAKING; CLINICAL RESEARCH; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; COST; DATA BASE; GOVERNMENT; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; MEDICAL SOCIETY; MEDICARE; METHODOLOGY; OBSERVATIONAL METHOD; ONCOLOGY; PATIENT CARE; PHARMACY BENEFIT MANAGER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; RESOURCE MANAGEMENT; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

COMPARATIVE EFFECTIVENESS RESEARCH; DATA INTERPRETATION, STATISTICAL; DECISION MAKING; HUMANS; MEDICAL ONCOLOGY; OBSERVATION; RESEARCH DESIGN;

EID: 84870683871     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.6701     Document Type: Review

References (93)

1. Marko NF, Weil RJ: The role of observational investigations in comparative effectiveness research. Value Health 13:989-997
2. Antman K, Amato D, Wood W, et al: Selection bias in clinical trials. J Clin Oncol 3:1142-1147, 1985
3. Dreyer NA, Tunis SR, Berger M, et al: Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood) 29:1818-1825
4. Johnson ML, Crown W, Martin BC, et al: Good research practices for comparative effectiveness research: Analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources - The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report: Part III. Value Health 12:1062-1073, 2009
5. Dreyer NA, Schneeweiss S, McNeil BJ, et al: GRACE principles: Recognizing high-quality observational studies of comparative effectiveness. Am J Manag Care 16:467-471, 2010
6. Levine MN, Julian JA: Registries that show efficacy: Good, but not good enough. J Clin Oncol 26:5316-5319, 2008
7. Zippin C, Lum D, Hankey BF: Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 76:2343-2350, 1995
8. Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review, 1975-2000. Bethesda, MD, National Cancer Institute, 2000
9. Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732-748, 1993
10. National Cancer Institute: Brief description of the SEER-Medicare Database. http://healthservices.cancer.gov/seermedicare/overview/
11. Warren JL, Klabunde CN, Schrag D, et al: Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 40:IV3-IV18, 2002 (suppl)
12. Warren JL, Harlan LC, Fahey A, et al: Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40:IV55-IV61, 2002 (suppl)
13. Potosky AL, Warren JL, Riedel ER, et al: Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 40:IV62-IV68, 2002 (suppl)
14. American Medical Association: AMA physician masterfile. http://www.ama-assn.org/ama/pub/about-ama/physician-data-resources/ physician-masterfile.page
15. US Department of Veterans Affairs: National patient care database. http://www.virec.research.va.gov/NPCD/Overview.htm
16. Baldwin LM, Adamache W, Klabunde CN, et al: Linking physician characteristics and Medicare claims data: Issues in data availability, quality, and measurement. Med Care 40:IV82-IV95, 2002 (suppl)
17. National Cancer Institute: Cancer Research Network. http://crn.cancer. gov/about/
18. American College of Surgeons: National Cancer Data Base. http://www.facs.org/cancer/ncdb/index.html
19. Healthcare Cost and Utilization Project: Nationwide Inpatient Sample. http://www.hcup-us.ahrq.gov/nisoverview.jsp
20. Stulberg JJ, Delaney CP, Neuhauser DV, et al: Adherence to surgical care improvement project measures and the association with postoperative infections. JAMA 303:2479-2485, 2010
21. Thomson Reuters: MarketScan Research Database. http://marketscan. thomsonreuters.com/marketscanportal/
22. OptumInsight: A unique set of strengths. http://www.optuminsight.com/ about/businesses/
23. Lamont EB, Herndon JE 2nd, Weeks JC, et al: Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst 98:1335-1338, 2006
24. Lamont EB, Herndon JE 2nd, Weeks JC, et al: Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care 46:303-308, 2008
25. Lamont EB, Herndon JE 2nd, Weeks JC, et al: Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst 97:1080-1083, 2005
26. Barron TI, Connolly RM, Sharp L, et al: Beta blockers and breast cancer mortality: A population-based study. J Clin Oncol 29:2635-2644, 2011
27. Birkmeyer JD, Stukel TA, Siewers AE, et al: Surgeon volume and operative mortality in the United States. N Engl J Med 349:2117-2127, 2003
28. Finks JF, Osborne NH, Birkmeyer JD: Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 364:2128-2137, 2011
29. Birkmeyer JD, Sun Y, Wong SL, et al: Hospital volume and late survival after cancer surgery. Ann Surg 245:777-783, 2007
30. Hollenbeck BK, Wei Y, Birkmeyer JD: Volume, process of care, and operative mortality for cystectomy for bladder cancer. Urology 69:871-875, 2007
31. Birkmeyer JD, Siewers AE, Finlayson EV, et al: Hospital volume and surgical mortality in the United States. N Engl J Med 346:1128-1137, 2002
32. Waljee JF, Greenfield LJ, Dimick JB, et al: Surgeon age and operative mortality in the United States. Ann Surg 244:353-362, 2006
33. Dimick JB, Goodney PP, Orringer MB, et al: Specialty training and mortality after esophageal cancer resection. Ann Thorac Surg 80:282-286, 2005
34. Hershman DL, Buono D, Jacobson JS, et al: Surgeon characteristics and use of breast conservation surgery in women with early stage breast cancer. Ann Surg 249:828-833, 2009
35. Hershman DL, Buono D, McBride RB, et al: Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer. J Natl Cancer Inst 100:199-206, 2008
36. Wright JD, Neugut AI, Wilde ET, et al: Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. J Clin Oncol 29:3408-3418, 2011
37. Crew KD, Neugut AI, Wang X, et al: Racial disparities in treatment and survival of male breast cancer. J Clin Oncol 25:1089-1098, 2007
38. Hill JS, McPhee JT, McDade TP, et al: Pancreatic neuroendocrine tumors: The impact of surgical resection on survival. Cancer 115:741-751, 2009
39. Mojica P, Smith D, Ellenhorn JD: Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol 25:1043-1047, 2007
40. Edwards BK, Brown ML, Wingo PA, et al: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97:1407-1427, 2005
41. Howe HL, Wingo PA, Thun MJ, et al: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93:824-842, 2001
42. Weir HK, Thun MJ, Hankey BF, et al: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95:1276-1299, 2003
43. Riley GF, Potosky AL, Klabunde CN, et al: Stage at diagnosis and treatment patterns among older women with breast cancer: An HMO and fee-for-service comparison. JAMA 281:720-726, 1999
44. Neugut AI, Fleischauer AT, Sundararajan V, et al: Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: A population-based study. J Clin Oncol 20:2643-2650, 2002
45. Schrag D, Rifas-Shiman S, Saltz L, et al: Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20:3999-4005, 2002
46. Schrag D, Gelfand SE, Bach PB, et al: Who gets adjuvant treatment for stage II and III rectal cancer? Insight from Surveillance, Epidemiology, and End Results-Medicare. J Clin Oncol 19:3712-3718, 2001
47. Potosky AL, Saxman S, Wallace RB, et al: Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol 22:3261-3268, 2004
48. Potosky AL, Harlan LC, Kaplan RS, et al: Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 20:1192-1202, 2002
49. Harlan LC, Clegg LX, Trimble EL: Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 21:3488-3494, 2003
50. Sundararajan V, Hershman D, Grann VR, et al: Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: A population-based study. J Clin Oncol 20:173-178, 2002
51. Harlan L, Brawley O, Pommerenke F, et al: Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol 13:93-100, 1995
52. Ballard-Barbash R, Potosky AL, Harlan LC, et al: Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst 88:716-726, 1996
53. Earle CC, Venditti LN, Neumann PJ, et al: Who gets chemotherapy for metastatic lung cancer? Chest 117:1239-1246, 2000
54. Schrag D, Cramer LD, Bach PB, et al: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93:850-857, 2001
55. Samet J, Hunt WC, Key C, et al: Choice of cancer therapy varies with age of patient. JAMA 255:3385-3390, 1986
56. Randall TC, Armstrong K: Differences in treatment and outcome between African-American and white women with endometrial cancer. J Clin Oncol 21:4200-4206, 2003
57. Bach PB, Cramer LD, Warren JL, et al: Racial differences in the treatment of early-stage lung cancer. N Engl J Med 341:1198-1205, 1999
58. Steyerberg EW, Earle CC, Neville BA, et al: Racial differences in surgical evaluation, treatment, and outcome of locoregional esophageal cancer: A population-based analysis of elderly patients. J Clin Oncol 23:510-517, 2005
59. Baldwin LM, Dobie SA, Billingsley K, et al: Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst 97:1211-1220, 2005
60. Bickell NA, Wang JJ, Oluwole S, et al: Missed opportunities: Racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24:1357-1362, 2006
61. Morris AM, Rhoads KF, Stain SC, et al: Understanding racial disparities in cancer treatment and outcomes. J Am Coll Surg 211:105-113, 2010
62. Patel DA, Barnholtz-Sloan JS, Patel MK, et al: A population-based study of racial and ethnic differences in survival among women with invasive cervical cancer: Analysis of Surveillance, Epidemiology, and End Results data. Gynecol Oncol 97:550-558, 2005
63. Rhoads KF, Ackerson LK, Jha AK, et al: Quality of colon cancer outcomes in hospitals with a high percentage of Medicaid patients. J Am Coll Surg 207:197-204, 2008
64. Michalski TA, Nattinger AB: The influence of black race and socioeconomic status on the use of breast-conserving surgery for Medicare beneficiaries. Cancer 79:314-319, 1997
65. McGory ML, Zingmond DS, Sekeris E, et al: A patient's race/ethnicity does not explain the under-use of appropriate adjuvant therapy in colorectal cancer. Dis Colon Rectum 49:319-329, 2006
66. Du XL, Fang S, Coker AL, et al: Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: Findings from a large community-based cohort. Cancer 106:1276-1285, 2006
67. Sanderson M, Coker AL, Perez A, et al: A multilevel analysis of socioeconomic status and prostate cancer risk. Ann Epidemiol 16:901-907, 2006
68. Lee CM, Szabo A, Shrieve DC, et al: Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA 295:389-397, 2006
69. Smith BD, Haffty BG, Buchholz TA, et al: Effectiveness of radiation therapy in older women with ductal carcinoma in situ. J Natl Cancer Inst 98:1302-1310, 2006
70. Hershman D, Jacobson JS, McBride R, et al: Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol 94:540-549, 2004
71. Dinan MA, Curtis LH, Hammill BG, et al: Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA 303:1625-1631, 2010
72. Smith BD, Pan IW, Shih YC, et al: Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst 103:798-809, 2011
73. Nguyen PL, Gu X, Lipsitz SR, et al: Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29:1517-1524, 2011
74. Hu JC, Gu X, Lipsitz SR, et al: Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 302:1557-1564, 2009
75. Giordano SH, Kuo YF, Freeman JL, et al: Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97:419-424, 2005
76. Doyle JJ, Neugut AI, Jacobson JS, et al: Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 23:8597-8605, 2005
77. Travis LB, Hill DA, Dores GM, et al: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290:465-475, 2003
78. Dores GM, Metayer C, Curtis RE, et al: Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol 20:3484-3494, 2002
79. Travis LB, Andersson M, Gospodarowicz M, et al: Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92:1165-1171, 2000
80. Socié G, Curtis RE, Deeg HJ, et al: New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 18:348-357, 2000
81. Travis LB, Holowaty EJ, Bergfeldt K, et al: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 340:351-357, 1999
82. Travis LB, Curtis RE, Boice JD Jr: Late effects of treatment for childhood Hodgkin's disease. N Engl J Med 335:352-353, 1996
83. Chaturvedi AK, Engels EA, Gilbert ES, et al: Second cancers among 104,760 survivors of cervical cancer: Evaluation of long-term risk. J Natl Cancer Inst 99:1634-1643, 2007
84. Baxter NN, Habermann EB, Tepper JE, et al: Risk of pelvic fractures in older women following pelvic irradiation. JAMA 294:2587-2593, 2005
85. Hassett MJ, O'Malley AJ, Pakes JR, et al: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117, 2006
86. Yabroff KR, Lamont EB, Mariotto A, et al: Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 100:630-641, 2008
87. Warren JL, Yabroff KR, Meekins A, et al: Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 100:888-897, 2008
88. Hollenbeck BK, Ye Z, Dunn RL, et al: Provider treatment intensity and outcomes for patients with early-stage bladder cancer. J Natl Cancer Inst 101:571-580, 2009
89. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763, 1997
90. Stukel TA, Fisher ES, Wennberg DE, et al: Analysis of observational studies in the presence of treatment selection bias: Effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 297:278-285, 2007
91. Hadley J, Yabroff KR, Barrett MJ, et al: Comparative effectiveness of prostate cancer treatments: Evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst 102:1780-1793, 2010
92. Harlan LC, Hankey BF: The Surveillance, Epidemiology, and End-Results program database as a resource for conducting descriptive epidemiologic and clinical studies. J Clin Oncol 21:2232-2233, 2003
93. Izquierdo JN, Schoenbach VJ: The potential and limitations of data from population-based state cancer registries. Am J Public Health 90:695-698, 2000